Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986154 | 0.84 | KMT2A (0.74) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL4254145 | 0.82 | MEN1 (0.80) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL9208778 | 0.82 | NPC1 (0.71) | ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30726106 | 0.82 | NPC1 (0.71) | ALDH1A1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6811505 | 0.82 | KMT2A (0.74) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL28015796 | 0.81 | KMT2A (0.58) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL3638667 | 0.81 | JAK2 (0.64) | SMN1; SMN2KMT2AMAPTMEN1HPGD | |
| SCHEMBL7120552 | 0.81 | MEN1 (0.62) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL31254103 | 0.81 | KMT2A (0.87) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT | |
| SCHEMBL28342284 | 0.81 | KMT2A (0.87) | ALDH1A1RAB9ASMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| EP-4171569-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | Council of Scientific & Industrial Research (IN) | 2023-05-03 | — | — | EP | disclosed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | ALDH1A1 295/4885RAB9A 1353/4885SMN1; SMN2 3760/4885 |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | ATG7, GOT1, ULK1 | ALDH1A1 601/4885RAB9A 1464/4885SMN1; SMN2 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.